This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

This study has been completed.
Information provided by (Responsible Party):
Novartis Identifier:
First received: January 10, 2007
Last updated: April 27, 2012
Last verified: April 2012
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 administered via intravenous infusion and subcutaneous injection in healthy Japanese male volunteers.

Condition Intervention Phase
Healthy Drug: ACZ885 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Demonstrate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered as Intravenous Infusion and Subcutaneous Injection in Japanese Healthy Volunteers

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Safety and tolerability

Secondary Outcome Measures:
  • Pharmacokinetics and pharmacodynamics

Estimated Enrollment: 48
Study Start Date: December 2006
Study Completion Date: December 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Japanese healthy male subjects age 20 to 45 years of age, and in good health
  • At screening and baseline, the subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis.
  • Body mass index within the range of 18 to 28 kg/m2 and weigh 50 to 100 kg

Exclusion Criteria:

  • Smokers.
  • Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable. Treatment of any biologics within three months prior to dosing. Having live vaccinations within six months prior to dosing.
  • Participation in any clinical investigation within 4 months prior to dosing.
  • Donation or loss of 400 mL or more of blood within 3 months; donation or loss of 200 mL or more of blood within 1 month; or donation of component blood within 2 weeks prior to participation.
  • Significant illness (sinusitis, pneumonia, cystitis, sepsis, etc) within two weeks prior to dosing.
  • A past personal or close family medical history of cardiac disorders
  • History of:

    • fainting,
    • low blood pressure when standing,
    • abnormal heart rhythms
    • acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
  • Clinically significant drug allergy or history and complication of atopic allergy (asthma, urticaria, eczematous dermatitis)
  • Known hypersensitivity to the study drug or similar drugs
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or jeopardize participation in the study.
  • History of immunodeficiency diseases, including a positive HIV test result.
  • A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or Syphilis test result.
  • Drug or alcohol abuse within the 12 months prior to dosing
  • Tuberculosis symptoms, complication of tuberculosis, contact with patients with suspected tuberculosis symptoms

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00421226

Novartis Investigative site
Tokyo, Japan
Sponsors and Collaborators
Principal Investigator: Novartis Investigator site
  More Information

Responsible Party: Novartis Identifier: NCT00421226     History of Changes
Other Study ID Numbers: CACZ885A1101
Study First Received: January 10, 2007
Last Updated: April 27, 2012

Keywords provided by Novartis:
Safety, tolerability, pharmacokinetics, pharmacodynamics, ACZ885, Japanese, processed this record on September 21, 2017